These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16217285)

  • 1. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder. A metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy.
    Montie JE
    J Urol; 2005 Nov; 174(5):1783-4. PubMed ID: 16217285
    [No Abstract]   [Full Text] [Related]  

  • 2. The management of superficial bladder cancer.
    Dalbagni G
    Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
    Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
    Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2004 Oct; 27(5):522-8. PubMed ID: 15596924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
    Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS; Schellhammer PF
    J Urol; 2007 Dec; 178(6):2314-30. PubMed ID: 17993339
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
    Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
    J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy of superficial bladder cancer].
    Schmitz-Dräger BJ; Schattka SO; Ebert T
    Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current problems and needs in the treatment of pT1 G3 bladder carcinoma.
    Martínez Portillo FJ; Alken P
    Int Urol Nephrol; 2002; 33(1):29-40. PubMed ID: 12090335
    [No Abstract]   [Full Text] [Related]  

  • 13. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    de Reijke TM
    Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guerin-refractory superficial bladder cancers: focus on pretreatment episodes.
    Okamura T; Akita H; Tozawa K; Kawai N; Nagata D; Kohri K
    Int J Clin Oncol; 2003 Jun; 8(3):168-73. PubMed ID: 12851841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.